Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenuin B
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Tenuin B is a naturally occurring phenanthrene small molecule isolated from the slender rush, *Juncus tenuis*. It was identified as part of a series of novel phenanthrenes (tenuins A-E) characterized for their potential anticancer properties. While some related phenanthrenes exhibit direct antiproliferative activity, tenuin B is specifically recognized for its potent chemosensitizing effects. In preclinical research, tenuin B demonstrated highly potent synergism when combined with doxorubicin against doxorubicin-resistant human colorectal adenocarcinoma cells (COLO 320), suggesting its potential as a lead compound for overcoming multidrug resistance in colorectal cancer therapy.
Beyond the preview
Go deeper on tenuin B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenuin B.